Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ronald C. Renaud Jr.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Beta
- 0.50
- Country
- US
Financials
KLRA has only 4 quarterly periods on file — the charts below show the full history available.
Net Income
$-95.67MEBITDA
$-106.34MFree Cash Flow
$-133.67MEPS (diluted)
$-0.74Shares Outstanding (diluted)
129.65M+9.9%Operating Expenses
$106.34MCash & Debt
$901.45MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-148.96M | $-1.26 |
Valuation
KLRAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·12d ago·Neutral
… presentation highlights the clinical unmet needs of people living with obesity WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
… to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Kailera Therapeutics to Participate in November Investor Conferences Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
…ions from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study…
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
Kailera Therapeutics to Participate in September Investor Conferences WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Wednesday, September 23, 2026, 9:40 a.m.
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $-0.90 per share
Typical surprise -21.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.74 vs $-0.73miss
- Wed, Aug 12$-1.09 vs $-0.90miss
- Tue, May 26$-3650.00 vs $-0.78miss
Estimates and results for KLRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KLRA officers and directors.
- Bought
- $326.8m
- Sold
- —
5 trades
0 trades
- Rtw Investments, Lpbought
- Bain Capital Investors Llcbought
- Koppel Adambought
- Bain Capital Life Sciences Investors, Llcbought
- Kaplan Andrew T.bought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KLRA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
